← Back to headlines
BofA Sees Limited Impact to Eli Lilly from Novo's GLP-1 Update
Bank of America analysts anticipate a limited impact on Eli Lilly's franchise despite Novo's recent GLP-1 price update.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
